GlassScriptPhysician profile
Marc A Lewandoski
NPI 1982676334
$2,959.35
in general payments reported to CMS, 2019-2025
21 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $410 · 2021: $455 · 2022: $457 · 2023: $412 · 2024: $506 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $519.96 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $494.13 | 2020-2024 | Airsupra, Breztri |
| Amarin Pharma, INC. | $287.82 | 2019-2021 | |
| Glaxosmithkline, LLC. | $260.74 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Allergan, INC. | $246.69 | 2020-2022 | |
| Abbott Laboratories | $214.01 | 2022-2024 | Freestyle Libre 3 |
| Pfizer INC. | $139.53 | 2019-2025 | |
| Lilly USA, LLC | $134.27 | 2019-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $117.94 | 2024-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $91.11 | 2019-2023 | Livalo |
| Abbvie INC. | $81.20 | 2022-2025 | |
| Depuy Synthes Sales INC. | $74.13 | 2021-2023 | Orthovisc |
| Merck Sharp & Dohme LLC | $73.55 | 2019-2020 | |
| Lundbeck LLC | $54.53 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $45.77 | 2022-2024 | Spravato |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $42.23 | 2024 | Korlym |
| Bausch Health US, LLC | $28.39 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.37 | 2024 | Cycloset |
| Shield Therapeutics INC | $14.89 | 2023 | Accrufer |
| Sanofi Pasteur INC. | $11.75 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Lewandoski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.